Real world use of lanreotide in neuroendocrine tumors.

Background

Treatment for metastatic neuroendocrine tumors (NETs) is often with somatostatin analogues (SSA) such as lanreotide in the first-line setting. Real world use of lanreotide in Canada is not well studied.

Methods

We performed a retrospective chart review of 69 patients to study real world use of lanreotide at our centre.

Results

Lanreotide was the first-line of systemic treatment in 60 patients. Watch-and-wait was a common strategy and was seen in 31 patients. SSA switch strategy was seldom applied. Majority of patients on lanreotide had low-grade NETs. Standard starting dose of lanreotide 120 mg every 28 days was used in 66 patients. Dose escalation to 120 mg every 21 days occurred in 7 patients. The primary intention for treatment was tumor control in 32 patients, and both tumor and symptom control in 34 patients. Median time on treatment was 21.6 months.

Conclusions

Overall, our findings were in keeping with current guidelines. It will be interesting to assess how clinical practice evolves in the future and to determine the role of dose escalation for disease control.

Informations de copyright

2023 Journal of Gastrointestinal Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-1182/coif). TA is a consultant for Ipsen and involved in enrolling patients in clinical trials. MV is a consultant for Amgen, a speaker for Merck and is involved in enrolling patients in clinical trials. RG is a member of advisory board for Ipsen, Pfizer, Eisai, Roche, Bayer, AAA and Apobiologix. She is a speaker for Merck, Viatris, Pfizer and Amgen. She received independent educational grants from Pfizer and Eisai and Apobiologix. She is also involved in enrolling patients in clinical trials. The other authors have no conflicts of interest to declare.